Invex Therapeutics (ASX:IXC) Scaled Net Operating Assets : -0.07 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Invex Therapeutics's operating assets for the quarter that ended in Dec. 2024 was A$0.06 Mil. Invex Therapeutics's operating liabilities for the quarter that ended in Dec. 2024 was A$0.48 Mil. Invex Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was A$6.12 Mil. Therefore, Invex Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was -0.07.

Invex Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Invex Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Scaled Net Operating Assets Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Scaled Net Operating Assets

-0.07

-0.02

-0.03

-0.04

-0.02

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Scaled Net Operating Assets	Get a 7-Day Free Trial						-0.02	-0.05	-0.04	-0.05	-0.07

Competitive Comparison of Invex Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Invex Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Scaled Net Operating Assets falls into.

Invex Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Invex Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2024 )
=	(Operating Assets (A: Jun. 2024 )	-	Operating Liabilities (A: Jun. 2024 ))	/	Total Assets (A: Jun. 2023 )
=	(0.095	-	0.432)	/	22.804
=	-0.01

where

	Operating Assets		(A: Jun. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	6.12	-	6.025
=	0.095

	Operating Liabilities		(A: Jun. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.432	-	0	-	0
=	0.432

Invex Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2024 )
=	(Operating Assets (Q: Dec. 2024 )	-	Operating Liabilities (Q: Dec. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(0.058	-	0.48)	/	6.12
=	-0.07

where

	Operating Assets		(Q: Dec. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.864	-	5.806
=	0.058

	Operating Liabilities		(Q: Dec. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.48	-	0	-	0
=	0.48

Invex Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.